| http://www.w3.org/ns/prov#value | - Mark is a member of the National Cancer Research Institute Melanoma Clinical Studies Group, leading several clinical trials in the UK national portfolio, and having responsibility for their translational research delivery.David Kerr has made sustained and internationally recognised contribution to cancer care and research in the field of drug development over the past 3 decades.
|
